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Simple Summary: Pancreatic cancer has a very low survival rate and improved treatments are
required. In addition to tumour cells, the disease is characterized by a significant non-tumour
cell stromal component including immune cells, blood vessels and, particularly, fibroblasts whose
normal role is in connective tissue and healing wounds. This stromal environment can affect tumour
progression and play a role in response to therapy. Whilst there is relatively good understanding of
the deregulated signalling in the tumour cells, less attention has been paid to the stroma until recently.
It is now apparent that there is significant variation within and between the stroma in different
tumours, in particular, between fibroblast populations. TGFβ is a growth factor that can play a role
in cancer cells, but also in shaping the tumour stroma. Here we review recent developments in our
understanding of the fibroblast populations within PDAC with a focus on TGFβ signalling.
Abstract: Pancreatic ductal adenocarcinoma is an aggressive disease for which there are very few
available therapies. It is notable for its high degree of tumour complexity, with the tumour microen-
vironment often accounting for the majority of the tumour volume. Until recently, the biology of
the stroma was poorly understood, particularly in terms of heterogeneity. Recent research, however,
has shed light on the intricacy of signalling within the stroma and particularly the molecular and
functional heterogeneity of the cancer associated fibroblasts. In this review, we summarise the recent
improvements in our understanding of the different fibroblast populations within PDAC, with a
focus on the role TGFβ plays to dictate their formation and function. These studies have highlighted
some of the reasons for the failure of trials targeting the tumour stroma, however, there are still
considerable gaps in our knowledge, and more work is needed to make effective fibroblast targeting
a reality in the clinic.
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1. Introduction
Over the last 50 years there has been very little improvement in survival of patients
diagnosed with pancreatic ductal adenocarcinoma (PDAC) with only 8% of patients in the
UK surviving 5 years post diagnosis [1]. Although new chemotherapeutic combinations
have been developed over that time [2–4], they have failed to provide a cure and shown
poor efficacy in terms of improving long-term survival. Surgical intervention remains
the best treatment modality, however, this is frequently hindered by anatomical location
preventing surgery or resection margin involvement, and survival is limited post-surgery
due to recurrence or emergence of metastatic disease. Ultimately, the development of new
therapies is required in order to combat the disease, especially with the prediction that
PDAC will become the third leading cause of cancer related death by 2030 [5].
With the failure of non-specific chemotherapy, patient stratification remains an attrac-
tive option to identify subsets of patients that would respond well to targeted therapies.
Constitutively active KRAS is found in 95% of PDAC cases, with mutations in TP53,
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SMAD4 and CDKN2A found in ~50% of cases. However, the publication of multiple hu-
man PDAC sequencing experiments has highlighted the abundance of low penetrance gene
mutations. These studies also allow for broad clustering of patients into specific cancer
subtypes while highlighting commonly dysregulated signalling pathways [6–8]. Patient
stratification based on either genetic aberrations or transcriptional subtypes may translate
to more effective and targeted therapies, such as in a DNA damage repair-deficient subset
of patients [9].
Evolving alongside the cancer cells, there is a significant stromal component in pan-
creatic cancer, consisting of fibroblasts and immune cells and an abundance of extracellular
matrix (ECM), together constituting up to 80% of the total PDAC. Although our under-
standing of the genetics of disease progression has improved, little attention has been paid
to this stromal infiltrate until more recently. A large proportion of the stroma is made of
cancer-associated fibroblasts (CAFs) which have been proposed to have both a tumour re-
straining and promoting function [10]. Recently, through single cell RNA sequencing, they
have been confirmed to exist as distinct subpopulations rather than a single homogenous
population within the tumour [11,12]. These subpopulations have specific localisation and
functionality, raising the question of whether specific population targeting through therapy
could be possible, although further understanding of these populations is required.
One of the major dysregulated pathways within PDAC is transforming growth factor
beta (TGFβ) signalling. The TGFβ signalling family is composed of 33 ligands and in its
simplest form involves ligation of a type II receptor which recruits and phosphorylates a
type I receptor at the cell surface to propagate intracellular signalling via SMAD molecules.
Complexity is imbued by the range of ligands and varied receptor combinations, as well
as cell and context specific functions. For instance, TGFβ has been shown to be potently
tumour suppressive in disease initiation as illustrated by the frequent mutations to sig-
nalling components, TGFβ-receptor-2 (TGFBR2), TGFBR1 and SMAD4 in human PDAC [6].
This has been confirmed by mouse modelling of the disease, where deletion of the afore-
mentioned genes results in rapid disease progression [13,14]. Yet TGFβ signalling is a
driver of epithelial mesenchymal transition (EMT) which is pertinent in driving metastasis
in progressed disease. For example, TGFβ secreted by CAFs drives invasive behaviour
in PDAC cell lines [15]. TGFβ ligand is abundant within PDAC [14], and, also, has an
important role in shaping the tumour stroma. It is a potent suppressor of both the innate
and adaptive arms of the immune system [16], as well as acting as an activator of CAFs
causing increase production of ECM components as well as increasing contractile functions.
In this review, we will discuss the recent improvements in our understanding of the
fibroblast populations within PDAC and the effects of therapeutic targeting, with a focus
on the role played by TGFβ signalling.
2. TGFβ Signalling Pathway in PDAC
TGFβ signalling has been shown to be a potent tumour suppressor in pancreatic
cancer. Disruption of signalling, primarily through SMAD4 loss, is detected in roughly 50%
of PDAC cases, and the tumour suppressive activity of the pathway has been demonstrated
in mouse models of PDAC, with deletion of SMAD4 alongside oncogenic Kras accelerating
PDAC progression, often via the development of intraductal papillary mucinous neoplasia
(IPMN) [14,17,18]. Further, the deletion of Tgfbr2 also accelerated KRAS-driven carcino-
genesis with a median survival of less than 2 months [13], highlighting the importance
of TGFβ signalling in epithelial cells. On the other hand, secretion of TGFβ by PDAC
stromal cells was found to negatively regulate L1CAM expression and drive a more ag-
gressive phenotype [19]. In contrast with previous studies suggesting a pro-metastatic
role for L1CAM [20–22], this study showed that L1CAM-low PDAC cells were less differ-
entiated and exhibited enhanced stemness phenotypes, including increased capacity for
self-renewal, tumour initiation, migration and invasion and chemoresistance [19]. Inter-
estingly, recent work also found that lowering cholesterol resulted in a switch to a basal
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phenotype of PDAC, reminiscent of the more aggressive basal/squamous subtype, via a
TGFβ1-mediated EMT [23].
TGFβ signalling has been shown to have an important role in the stromal reaction
in cancer [24], and specifically in PDAC. For instance, orthotopic injection of Panc1 cells
over expressing TGFβ1 has been shown to increase desmoplasia [25]. In vitro, addition of
TGFβ to cultured pancreatic stellate cells (PSCs) results in increased expression of alpha
smooth muscle actin (αSMA) and increased collagen synthesis [26], but also secretion of
matrix metalloproteases indicative of a role in stromal remodelling [27]. Conversely, ECM
synthesis by PSCs in response to conditioned medium from PDAC cell lines was abrogated
by TGFβ neutralizing antibody [28]. One of the earliest studies of the effects of TGFβ
signalling in the pancreas in vivo found that overexpression of TGFβ1 driven by an insulin
promoter increased fibroblast infiltration and fibrosis, with the exocrine pancreas almost
completely replaced by fibroblasts and ECM deposition [29]. More recently, the dual role of
TGFβ signalling in pancreatic cancer was demonstrated in PDAC mouse models with either
epithelial or systemic Tgfbr1 deletion. Epithelial depletion of the type 1 receptor promoted
pancreatic tumourigenesis, in line with findings in Smad4 and Tgfbr2 deficient models,
however, systemic depletion revealed important TGFβ-mediated control of the tumour
microenvironment (TME). Tumourigenesis was delayed, production of TGFβ ligand by
the stroma was diminished as a result of the disruption of positive feedback caused by
receptor depletion, and tumour-associated fibrosis was decreased. In addition, the TME
was converted to a less immunosuppressive state, with a decrease in Treg infiltration
and significant CD8+ T cell infiltration observed [30]. Further, TGFβ-R2 blockade, in
the p48-Cre; LSL-KrasG12D; Cdkn2alox/lox autochthonous model of PDAC and in orthotopic
models, resulted in a reduction in αSMA fibroblasts with a subsequent reduction in collagen
deposition, tumour cell differentiation and reduced metastases [31]. Together, these studies
demonstrate an important role for TGFβ signalling in the development of the dense stroma
associated with PDAC.
In terms of the downstream effects of TGFβ signalling in the stroma, TGFβ treatment
of both fibroblasts and CAFs has been shown to lead to increased cell stiffness, and
specifically in CAFs, to enhanced cell elongation and spreading, formation of lamellipodia
and invasion. Mechanistically, these changes are accompanied by increased Rac, RhoA and
ROCK [32]. Biffi et al. (2019) also showed that TGFβ can promote the transformation of
fibroblasts to myofibroblastic CAFs in PDAC [33]. This subtype will be discussed in more
detail later.
3. Fibroblasts within PDAC
In PDAC, a large proportion of the TME is composed of CAFs, which develop along-
side the growing tumour and contribute significantly to fibrosis. The ECM of both primary
and metastatic sites of PDAC is composed of significant levels of collagens I, III and IV, as
well as hyaluronan, with high levels denoting worse prognosis [34]. Stromal cells have been
shown to produce more than 90% of the ECM, with collagens comprising the vast majority,
and the complexity of this matrix increases as disease progresses [35]. Mouse modelling
has revealed that CAFs and malignant cells are intrinsically linked, with a tetracycline
inducible oncogenic Kras model demonstrating resolution of neoplastic regions, but also
of the associated infiltrated stroma, upon ‘switching off’ of oncogenic Kras [36]. However,
the source of CAFs has yet to be fully resolved due, in part, to the inability to track them
in human disease. The general consensus was that they arise from the resident PSCs that
become activated by factors released by the neoplastic cells, but recent studies suggest that
further investigation is required.
PSCs were initially isolated from the rat pancreas [37] and were shown to become
activated in PDAC with increased expression of αSMA and loss of the vitamin A-containing
lipid droplets characteristic of quiescent PSCs. [38]. They were shown to be major producers
of ECM proteins, including collagens, laminin, fibronectin and hyaluronan, and found to
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accelerate the growth of subcutaneous tumours when co-injected together with tumour
cells in transplant models [26,28,39].
It has also been demonstrated, however, that CAFs isolated from human PDAC
can arise from mesenchymal stem cells (MSCs). Waghray and colleagues found that a
population of these CAFs expressed multiple MSC markers in addition to bona fide CAF
markers vimentin, fibroblast activation protein (FAP) and αSMA. These MSC-derived CAFs
secreted various cytokines such as IL-6 and IL-8 but exclusively expressed granulocyte
macrophage-colony stimulating factor (GM-CSF) differentiating them from other CAFs.
The production of GM-CSF from these cells was able to enhance invasion of cultured
cancer cells [40].
Further, it has recently been shown that CAF-like cells may be derived from bone
marrow (BM)-derived monocytes that infiltrate the tumour. Transplantation of GFP-
positive BM into spontaneous mouse models of PDAC highlighted a population of GFP,
F4/80 and podoplanin (PDPN) positive cells, a macrophage and pan fibroblast marker,
respectively, found even in MSC depleted samples. These cells were shown to be either
αSMA positive or negative and able to produce an array of cytokines in culture, including
IL-10 and IL-6 [41].
Recently, lineage tracing of Gli1+ and Hoxb6+ fibroblast within the pancreas high-
lighted divergent expansion upon oncogenic transformation. Intriguingly, the authors
show the existence of both PSCs and fibroblasts (lacking lipid droplets) within the healthy
pancreas, with Gli1+ fibroblasts found in perivascular regions and Hoxb6+ fibroblasts
scattered throughout the pancreatic parenchyma [42]. Whereas Hoxb6+ fibroblasts failed to
expand upon development of neoplasia, the Gli1+ fibroblast population was shown to ex-
pand and contribute to the αSMA+ fibroblast population during tumourigenesis. However,
in terms of αSMA expression, heterogeneity existed across Gli1+ lineage cells [42]. Interest-
ingly, there is evidence for reciprocal signalling between the TGFβ and sonic hedgehog
(SHH) pathways. In basal cell carcinoma (BCC), Gli1 was found to be induced in response
to TGFβ signalling in a Gli2-dependent, but SHH independent manner [43]. Conversely,
TGFβ2 was identified as a HH target gene in BCC driven by the essential SHH signalling
component, smoothened (SMO) [44]. Crosstalk between the pathways has also been de-
scribed in human lung fibroblasts. TGFβ1 was shown to regulate expression of hedgehog
pathway components, independent of SMO. However, SMO, along with GLI1-dependent
transcription, was required for TGFβ-mediated differentiation of normal fibroblasts to a
myofibroblast phenotype [45]. The impact of crosstalk between these pathways on CAF
function and phenotype in PDAC is, as yet, unknown, but worthy of further investigation.
Together these studies suggest that fibroblast heterogeneity is present in the normal
pancreas but is also derived from the infiltration or expansion of cells in pancreatic tumours
that can develop CAF-like features and functions. More recently, the field has begun
to appreciate that CAFs in PDAC may differ not only in their cell of origin but also in
function [46]. These fibroblast subpopulations can respond differently to tumour growth,
while also differing in their production of growth factors or cytokines that, in turn, can
influence tumourigenesis (Figure 1). Further work, however, is required to ascertain
whether CAFs of different phenotypes are derived from distinct progenitors or are educated
by their surroundings.
It is important to understand how these heterogeneous populations of CAFs can
influence tumour cells and other cells in the TME and to characterize the crosstalk between
different cell populations. Indeed, communication between CAFs and tumour cells is highly
complex, and not limited simply to one directional paracrine signalling. For example, CAFs
and tumour cells can form a reciprocal signalling loop, whereby CAFs educated by the
tumour cells can in turn impact oncogenic signalling in the cancer cells. In one study,
KRASG12D-transformed cancer cells were shown to regulate the secretome of PSCs [47].
Intriguingly, conditioned media from these tumour cell-educated PSCs could further
alter the tumour cell phosphoproteome, beyond the cell-autonomous changes driven by
oncogenic KRAS. Most notably, tumour cell autonomous KRASG12D was sufficient to drive
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MEK-ERK signalling but not AKT activation, which required secretion of IGF1 and GAS6
by the PSCs [47]. Further, co-culture of CAFs with PDAC cells culminates in enhanced
clonogenic growth as well as an increase in cancer cell EMT [48]. Transcriptional and
proteomic investigation revealed that matrisome genes are expressed by both pancreatic
tumour and stromal cells, and that this is also mediated by tumour-CAF crosstalk in a
bromodomain and extraterminal (BET) family protein dependent manner. The BET family
of chromatin adaptors, which contain tandem bromodomains allowing interaction with
acetylated lysines on target proteins and recruitment of transcriptional complexes to gene
regulatory elements, have been implicated in pancreatic tumourigenesis. Disruption of
this tumour-CAF crosstalk, using BET inhibition, resulted in reduced tumour growth
in vivo [49]. Together these studies point to the importance of the stromal crosstalk in
maintaining and driving the signalling required to promote cancer progression.
Figure 1. Paracrine CAF signalling influences multiple cell types in the TME.
As well as stimulating EMT, the fibrotic stroma driven by CAFs has been proposed
to impair drug delivery into tumours resulting in highly chemoresistant tumours [50].
Targeting of the stroma has therefore been considered a promising avenue for therapeutic
development over the last few years, however, stromal targeting therapies have so far been
unsuccessful in the clinic. Recent findings in preclinical models and in human tumour
samples have suggested that at least some of the biology attributable to CAFs may restrict
tumour progression and have led to a redoubling of efforts to understand CAF biology and
functional heterogeneity.
4. Inter- and Intra-Tumoural Fibroblast Heterogeneity
Multiple studies have sequenced human PDAC and have exposed a range of cancer
specific subtypes, highlighting multiple high and low penetrance mutations across the
disease [51]. Until recently, however, sequencing studies focused on analysis of bulk tumour
samples, with limited appreciation of the contribution of the tumour-associated fibroblasts.
Initial work on dissecting stromal specific signatures by Moffitt et al., utilised bulk RNA
data with a ‘virtual microdissection’ to split gene signatures into stromal- and cancer
cell-specific gene sets. They highlighted the existence of two stromal subtypes termed
‘normal’ or ‘activated’ by comparison to a stromal defining gene set, as well as a ‘classic’
and ‘basal-like’ subtype derived from the tumour cells. The ‘activated’ stromal subtype was
enriched for FAP, WNT family members, and genes related to immune cell recruitment (e.g.,
CCL13 and CCL18) and ECM remodelling (SPARC, MMP9 and MMP11), whilst the ‘normal’
subtype was enriched for markers associated with PSCs, e.g., αSMA, vimentin and desmin.
The stromal subtype was not affected by tumour subtype, with both subtypes observed at
similar frequency with either the classical or basal tumour subtype. However, ‘activated’
stroma correlated with reduced survival, regardless of tumour subtype [52]. Studies
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on RNA extracted from formalin-fixed paraffin-embedded resected PDAC specimens
confirmed the classifications of ‘classical’ and ‘basal-like’ from high tumour cellularity
samples, however when including all samples, regardless of tumour cellularity, a further
three subsets were identified resulting from the impact of the high stromal content and
microenvironment-derived signatures. Of these, the ‘immune-classic’ tumours were highly
infiltrated by natural killer, T and B cells, but few fibroblasts or inflammatory cells, the
‘stroma-activated’ tumours had higher fibroblast and endothelial cell involvement and low
immune cell infiltration, while the ‘desmoplastic’ subtype was characterized by infiltration
of fibroblasts, endothelial cells and all immune cell types [53]. Further work, utilising
laser capture microdissection to excise stromal and epithelial areas to generate specific
transcriptional signatures, again revealed two stromal and two cancer cell subtypes. The
stroma ‘ECM-rich’ and ‘Immune-rich’ transcriptional subtypes displayed enrichment for
gene sets associated with ECM deposition or immune signalling, respectively, with the
tumour epithelium classified as ‘classical’ or ‘basal-like’. Interestingly, in this work the
ECM-rich stroma subtype was more likely to be associated with the basal-like tumour
subtype, and combined, the ECM-rich stromal and ‘basal-like’ epithelial subtypes correlated
with poorer survival [54]. Birnbaum et al. also performed laser capture microdissection of
PDAC samples and identified three subtypes of cancer-adjacent stroma (which were named
S1–S3) and four cancer cell subtypes (named C1–C4). The stromal subtypes were enriched
for gene sets involved in development and cell differentiation (S1), antigen processing
and presentation (S2), and phospholipid synthesis and modification of macromolecules
(S3). When compared with the Moffitt et al. stromal subtypes, the S1 subtype most closely
aligned with the ‘normal’ subtype and was associated with better prognosis, whilst the S2
gene expression signature was enriched in the ‘activated’ subtype [55].
These findings highlighted the inter-tumoural heterogeneity of the PDAC stroma and
suggested that a specific stromal signature could influence patient prognosis. They con-
vincingly show that patients can present with different stromal composition within PDAC,
with cancer cell subtype not necessarily defining a specific stromal type, although combi-
nations of each may predict worse outcomes. However, there are limitations in analysing
CAF-specific functions when analysing bulk stroma, which incorporates CAFs, immune
cells and endothelial cells. Therefore, subsequent studies have applied CAF culturing,
single cell sequencing (scRNA-seq) and cytometry by time of flight (CyTOF) to investigate,
at single cell or population resolution, the fibroblast heterogeneity within PDAC.
RNA sequencing of low passage CAFs derived from human PDAC samples high-
lighted both inter- and intra-tumoural CAF heterogeneity, with four subtypes defined.
From the transcriptional signatures, the authors of this study were able to define specific
markers for subtypes A, B and C, (periostin, PDPN and myosin heavy chain 11 (MYH11),
respectively), which stained in distinct spatial regions of PDAC [56]. Interestingly, PDPN
has been shown to be a pan-fibroblast marker in PDAC in a subsequent study [12]. Here
periostin-positive CAFs were located in the centre and at the invasive edge of tumours,
whilst PDPN and MYH11 were found only in the centre. Although patients showed
intra-tumoural subtype heterogeneity, they could be stratified based upon their dominant
subtype from bulk tumour analysis, with subtype A, which also expressed low levels of
αSMA, being the most dominantly expressed at both intra- and inter-tumoural level. Sub-
type D was associated with the poorest prognosis while patients with subtype C enriched
tumours showed significantly longer survival than the other groups. In co-culture, subtype
A appeared to exhibit a less pro-tumoural phenotype. Interestingly, the authors also found
evidence of cancer cell education of the PSCs, with a decrease in the low αSMA-expressing
subtype A and an increase in subtypes B and C when exposed long term to tumour cell
conditioned medium [56]. In other work, culturing of PSCs in a 2D environment has been
reported to cells towards a high αSMA-expressing myofibroblastic phenotype [57], perhaps
highlighting the need to consider culture conditions carefully when investigating CAF
biology ex vivo.
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Extensive work from the Tuveson lab has uncovered three distinct fibroblast subpop-
ulations within PDAC, termed ‘myCAFs’, ‘iCAFs’ and ‘apCAFs’. Initial work, both in
organoid co-cultures and in vivo, documented the existence of myofibroblast-type (my-
CAF) and inflammatory (iCAF) CAFs. The myCAF population was shown to exist in close
proximity to neoplastic cells, expressed high levels of αSMA and TGFβ response genes,
and was largely responsible for ECM deposition. In contrast, the inflammatory CAFs
(iCAFs), named for their chemokine secreting capability, were found distant from cancer
cells, expressed significantly lower levels of αSMA, and instead were characterized by
secretion of factors such as Il-6, Il-11, LIF, CXCL1 and CXCL2 [57]. Both subtypes could
be derived from PSCs in vitro with appropriate stimulation. Formation of myCAFs could
be induced by 2D monolayer culture, but in organoid co-culture, required close-contact
with tumour cells. In contrast, only conditioned medium from cancer cells was required
for iCAF formation. Interestingly, these phenotypes were dynamic, since alternating cul-
ture conditions could mediate subtype switching [57]. Mechanistic work revealed cancer
cell-secreted TGFβ and IL-1 as the key drivers of these CAF populations. TGFβ signalling
via Smad2/3 was shown to be active in myCAFs, with TGFβ treatment able to drive a
myofibroblast phenotype in PSCs in vitro. In contrast, the iCAF phenotype was driven
by an IL-1-induced LIF/JAK/STAT pathway. Importantly, TGFβ signalling was shown to
inhibit the iCAF phenotype by directly inhibiting IL-1R1 expression, and thus preventing
JAK/STAT signalling, suggesting a role for TGFβ is a master regulator of CAF identity in
PDAC [33]. TGFβ is secreted in its latent form and its perfusion through the ECM may be
limited, perhaps explaining the distinct spatial location of iCAFs distal from the tumour
cells. Further single cell sequencing of dissociated human PDAC confirmed the identity of
these two CAF populations but also identified a third, antigen presenting, CAF subpop-
ulation, named apCAFs. Interestingly, the S3 stromal signature described by Birnbaum
et al. showed significant correlation with this CAF subpopulation [55]. These apCAFs were
shown to be MHCII and CD74 positive, and were able to present antigen to T cells in vitro,
however, they lack additional co-stimulatory molecules found in professional antigen
presenting cells [12]. The distinct advantage these experiments is that the function and
location of these CAFs have been defined alongside their distinct transcriptional profile,
lending power to the conclusion that these are bona fide CAFs subpopulations. What is
less clear is how these CAF populations relate to tumour subtype. One clue came from a
study investigating the effects of secreted factors from basal/squamous pancreatic cancer
cells on PSCs. This resulted in conversion to CAFs that express high levels of inflammatory
cytokines, reminiscent of iCAFs, by a p63 dependent mechanism [58].
Distinct fibroblast populations were also identified in a study in which the authors
performed scRNA-seq on normal pancreas, PanIN-bearing pancreas and PDAC from
the Ptf1aCre/+; KrasLSL-G12D/+; Ink4afl/fl (KIC) mouse model of PDAC, before validation in
a p53-deficient model. They demonstrated that three populations of fibroblasts were
present in normal pancreas and in expanded numbers in early lesions, however, in PDAC
this converged to just two fibroblast populations [11]. In the first of these (named FB1),
PDAC-associated populations expression of IL-6 and PDGFRα were enriched, while the
other population (named FB3) was enriched for the TGFβ-responsive markers αSMA and
TAGLN, mirroring the subpopulations definition by Elyada et al., as iCAFs and myCAFs,
respectively [11,12]. CD74 and MHCII, markers for the apCAF population, were enriched
in, but not exclusive to, the latter population.
Further confirmation of these CAF subtypes was provided by Steele et al., when they
analysed a single cell sequencing data set of PDAC [59,60]. However, they go further
to suggest that within the three defined overarching subtypes there may exist further
distinct populations that are dependent upon other signalling pathways. For instance, SHH
signalling was shown to be enriched within a subset of myCAFs compared with iCAFs [60].
Yet another marker that could distinguish CAF populations was identified by the
Turley lab. They conducted single cell sequencing of PDPN+ fibroblasts from murine
PDAC and observed several transcriptionally distinct CAF populations which converged
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into two populations driven by IL-1 or TGFβ, reminiscent of iCAFs and myCAFs. The
TGFβ-driven population represented ~60% of all CAFs in late-stage tumours, despite
being absent in normal pancreas, and was defined by expression of the leucine-rich repeat
containing 15 (LRRC15) protein. This population was also observed in human tumours,
with clinical trial data showing that the LRRC15+ CAF signature was associated with poor
response to immunotherapy, suggesting an immunosuppressive role for these cells [61].
Other CAF markers which imply CAF plasticity have been identified. For example,
Fujiwara et al. found that the putative mesenchymal stem cell marker, CD271, was elevated
in the stroma of PDAC compared to normal pancreas, predominantly at the tumour periph-
ery. However, high stromal CD271 expression was associated with improved prognosis in
pancreatic cancer patients. In PSC-tumour cell co-culture experiments, CD271 expression
in PSCs was increased initially, but decreased upon prolonged co-culture, suggesting that
expression decreases after prolonged exposure to tumour cells [62]. A more recent study
also found that CD271 expression was elevated in peripheral CAFs compared with those in
close proximity to tumour cells. Intriguingly, however, in patients receiving neo-adjuvant
FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin), regressive stroma be-
came evident and CAFs within these regions now exhibited higher CD271 expression [63].
These data raise the possibility that chemotherapy can mediate a switch in CAF subtype.
However, the functional relevance of CD271 expression is yet to be explored.
Recently, the transcription factor, paired-related homeobox 1 (PRRX1), has also been
suggested to play a role in CAF plasticity. It was reported to be highly expressed in CAFs
in both mouse and human PDAC, with stromal PRRX1 expression correlating with the
basal/squamous PDAC subtype. In mouse models, fibroblast-specific Prrx1 deletion led to
more differentiated, less metastatic tumours, alongside changes to the tumour ECM, and
this phenotype was attributed to release of hepatocyte growth factor (HGF) driving EMT in
tumour cells [64]. This was reminiscent of, yet in contrast to previous findings describing
isoform-specific roles of PRRX1a and 1b in pancreatic cancer cells, with PRRX1b promoting
HGF-mediated invasion, tumour dedifferentiation and EMT in the primary tumour, and
PRRX1a driving differentiation and mesenchymal-epithelial transition at distant sites [65].
One open and interesting question is whether PRRX1 in CAFs could play a role at distant
sites. Intriguingly, Prrx1-deficient CAFs recapitulated many of the features of myCAFs, but
unlike myCAFs, were fixed in their activated state when cultured in Matrigel, suggesting
that PRRX1 may be key for mediating CAF plasticity.
Recently, the Jørgensen lab described an alternative CAF classification based on ex-
pression of CD105, a co-receptor for TGFβ. Using mass cytometry to analyse the stroma in
pancreatic tumours arising in autochthonous mouse models they identified two function-
ally distinct pancreatic fibroblast lineages which were also present in normal pancreas as
well as in human PDAC and normal healthy pancreas. The CD105+ fibroblasts were more
abundant in tumours, however, CD105- CAFs were more proliferative within tumours,
and a minority of tumours showed an abundance of CD105- CAFs [66]. Of the previously
described CAF markers, most showed variable expression in both CD105+ and CD105-
CAFs indicating the presence of both myCAFs and iCAFs in each population although
the CD105- population was enriched for apCAF markers. Functionally, TGFβ signalling
was enriched in CD105+ CAFs whilst TNF-α, NF-κB, IL6, JAK2 and STING1 signalling
were differentially enriched in the CD105- population. Interestingly, and in contrast to
the iCAF/myCAF classification, CD105+/ CD105- CAFs remained ‘locked’ in their initial
state during long term mono-culture and, also, in response to treatment with TGFβ1 or
incubation with tumour cell-conditioned medium or in tumour cell co-culture. In cultures
of normal pancreatic fibroblasts (PaFs), the ratio of CD105+ and CD105- fibroblasts was also
maintained in response to most treatments, with the exception of TGFβ1, which increased
the proportion of CD105+ PaFs, and TNFα and IFNγ, which increased the proportion of
CD105- PaFs. IFNγ also caused an increase in apCAF markers in both CD105+ and CD105-
fibroblasts, which could be inhibited, again in both populations, by TGFβ1 [66].
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In co-transplant experiments in mice, CD105+ PaFs were permissive for tumour
growth in that they did not significantly influence tumour volume. However, CD105- PaFs
were revealed to be highly tumour-suppressive—co-injection of this population markedly
constrained tumour growth and led to improved survival, an effect recapitulated even
when a 1:1 mixed population of fibroblasts were co-injected. CD105- co-injected tumours
showed increased infiltration of dendritic cells (DCs) and CD8 T cells, and pathway analysis
revealed an enrichment for pathways involved in tumour-suppressive immune responses
including DC maturation and T cell activation, suggesting this tumour-restrictive effect
is dependent on adaptive immunity. Indeed, the tumour suppressive effect was lost in
immunodeficient mice and in mice lacking conventional type 1 dendritic cells (cDC1s).
Although no signalling capacity has been reported downstream of CD105, it has been
shown to alter the affinity of ligands for the TGFβ receptor complex and deletion of Eng,
the gene encoding CD105, from CD105+ CAFs did reduce transcriptional responses to
TGFβ1 treatment. Interestingly, however, any function attributable to CD105 did not play
a role in tumour suppression, since Eng deletion from CD105+ cells was not sufficient to
affect tumour growth [66].
Collectively, these papers highlight inter- and intra-tumoural heterogeneity through
multiple techniques (Figure 2).
Figure 2. CAF subtypes.
It is worth noting the caveats of these single cell systems, which involve the dis-
sociation of the tumour with the potential of altering the cell transcriptome. However,
combining these data with functional data and in situ validation in tumour tissue has
allowed verification of the findings of the single cell experiments. Although our under-
standing continues to improve, a consensus is still to be met upon fibroblast subpopulations
definitions. Across studies, subtypes have varied in definition, with different IHC markers
defining different subpopulations. It is key, not only to pinpoint bona fide markers for
these subsets, but also to better understand the function of these sub-populations and the
effects of their manipulation in complex tumours in order to enable the stratification of
patients and understand how variations in CAF composition of patient tumours might
represent therapeutic vulnerabilities.
5. Genetics of PDAC Influence CAF Education
Adding a further layer of complexity, the genetics of PDAC may directly impact the
TME with, for instance, the loss of SMAD4 resulting in a stiffer fibrosis which correlates
with a poorer survival [67]. Work in Tgfbr2 deficient mice highlighted a similar phenotype
with a stiffer ECM in comparison to the gold standard KPC (Pdx1-Cre; LSL-KrasG12D/+;
LSL-Trp53R172H/+) model [67], and this was found to be mediated by JAK-STAT3 signalling.
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In addition, the authors of this study described a feed-forward loop, by which the TME
amplifies JAK–STAT signalling and a β1-integrin–FAK–ROCK mechanosignalling cas-
cade to promote tumour aggressiveness [67]. Interestingly, in their CAF depletion study,
Ozdemir et al. utilised Tgfbr2 deficient mice to show that myofibroblast depletion led to
more aggressive tumours and reduced survival, although they obtained similar results in
the KPC model [68].
Recurrent mutations in the SLIT/ROBO pathway have been described in human
PDAC [69] and may also impact on TGFβ signalling and the TME. For example, loss of
epithelial ROBO2 expression and coincident upregulation of ROBO1 in the stroma has
been reported in PDAC. In mixed cell cultures from the pancreata of mice with pancreatic
epithelium-specific Robo2 deletion, expansion of ROBO1+ activated myofibroblasts was ob-
served along with induction of TGFβ signalling. In vivo, the Robo2-deficient mice exhibited
TGFβ-dependent increased fibroblast activation, fibrosis and immune signalling markers
in response to experimental pancreatitis, while in PDAC patients, low ROBO2 expression
high ROBO1 expression were associated with poorer survival. Thus, perturbations in
ROBO1/2 signalling could indicate a patient subgroup who could respond to TGFβ or
stromal targeting agents [70].
Even different mutations within the same gene may affect CAF biology. CAFs from
p53R172H mutant KPC tumours were shown to create a more collagen dense environment in
comparison to those isolated from p53-deficient KPflC (Pdx1-Cre; LSL-KrasG12D/+; Trp53fl/+)
tumours [71]. The gain-of-function p53R172H tumour cell-educated CAFs created a stiffer
matrix that could enhance the invasion of the less metastatic p53-deficient cancer cells,
potentially via secretion of perlecan, which was elevated in mutant p53-educated CAFs, as
well as in the stroma of KPC vs. KPflC PDACs. Interestingly, given its role in driving the
iCAF phenotype, TNFα was able to enhance perlecan expression by the KPflC educated
CAFs [33,72]. Gain-of-function p53 mutations have also been shown to correlate with
increased ECM deposition and the exclusion of cytotoxic CD8+ T cells in mouse and
human PDAC [73].
Epigenetic changes may also influence CAF plasticity. For example, matrisomal gene
expression was shown to be dependent on BET family proteins mediating crosstalk be-
tween tumour cells and CAFs, with a small molecule inhibitor able to alter matrisome gene
expression and inhibit tumour growth in mouse models [49]. Xiao et al. also showed that
tumour cells can influence CAFs through epigenetic changes. In co-culture experiments
they found that direct contact with PDAC cells led to methylation of SOCS1 in CAFs, via the
DNA methylation enzyme DNMT1. SOCS-1 methylation and consequent downregulation
resulted in enhanced STAT3-induced IGF-1 expression by the CAFs and promotion of
cancer cell proliferation and survival [74]. Further epigenetic analysis of CAFs from human
PDAC revealed extensive loss of cytosine methylation with multiple genes encoding inflam-
matory secreted factors, including CXCR4, showing differential hypomethylation resulting
in overexpression. Inhibition of CXCR4 could reduce CAF-mediate invasiveness of cancer
cells in co-culture. Mechanistically, lactate secreted by PDAC cells was shown to lead to
production of alpha-ketoglutarate in mesenchymal stem cells, which in turn activated the
ten-eleven translocation (TET) demethylase enzyme leading to decreased cytosine methy-
lation and elevated hydroxymethylation during conversion to CAFs [75]. Interestingly,
the basal/squamous PDAC subtype has been associated with loss of hydroxymethylation
via reduced expression of the TET2 5-methylcytosine hydroxylase. Importantly, however,
in this study the loss of 5-hydroxymethylcytosine was restricted to pancreatic epithelial
cells, with levels remaining high in stromal cells [76], in keeping with the previous findings.
Intriguingly, the authors did show that, at least in tumour cells, loss of SMAD4 expression
correlated with reduced hydroxymethylation, implicating TGFβ signalling as an additional
regulator of hydroxymethylation.
It is not surprising to note that the genetic aberrations within PDAC, which have the
capacity of altering the wider TME through direct and long-range signalling, can influence
the CAFs. It does, however, add complexity to our understanding of CAF subtyping with
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the predominance of work focussing on the KPC mouse model, reflecting the frequent
gain of function p53 subtype of human patients. It will be interesting to discover whether
the current CAF subtyping definitions are similar in other genetic models of PDAC, and
whether the subtype proportions change with differing genetic education. Examination
of late-stage tumours in the KIC, KPC and Pdx1Cre; KrasLSL-G12D/+; Trp53fl/fl mouse models
of PDAC has highlighted a similar clustering of CAFs [11], suggesting that these genetic
permutations do not greatly affect the overarching sub-classification of CAFs at least at
transcriptional level. In support of this, similar CAF subsets have been observed across
different cancer types with varying genetics, including breast, ovarian, head and neck and
lung cancer [77,78]. Conversely, tumour cells can elicit diverse effects on CAF phenotype,
irrespective of genetic aberrations. For example, the Trumpp lab described two PDAC
subgroups, based on DNA methylation and expression of an IFN-linked transcriptional
program, with methylation low/IFN high tumours exhibiting a more aggressive phenotype.
These subtypes were linked not to tumour genetics but to cell-of-origin, with ductal lineage
tumours exhibiting the IFN high signature. Investigation of the impact of tumour cell
subtype on CAF programming revealed differential gene expression in PSCs cultured in
medium conditioned by tumour cells of these subgroups, with IFN high subtype tumour
cells driving expression of genes associated with inflammatory programs, reminiscent of
iCAFs [79]. However, in most of these studies, it should be noted that the functionality of
CAF subtypes across different models has not yet been examined.
6. Therapeutic Intervention
With the general failure of frontline therapies in the treatment of PDAC, extensive
research has been conducted to identify new therapeutic avenues. Stratified therapy
appears an exciting option due to the ability to cluster patient subsets based on genetic
permutations, which may expose new vulnerabilities. However, as our understanding of
fibroblasts heterogeneity increases, this field may provide new targets to influence ‘good’
or ‘bad’ fibroblasts or to reprogram the TME.
Early studies in PDAC suggested that the fibrotic stroma could restrict chemother-
apeutic penetrance, and therefore proposed therapeutic targeting of stromal elements in
combination with chemotherapy. In 2009, work by Olive and colleagues in PDAC mouse
models found that targeting SHH signalling, a known driver of desmoplasia in pancreatic
cancer [80], could deplete the tumour stroma, improve tumour vascularity and enhance
delivery of standard-of-care gemcitabine into tumours, resulting in increased survival [81].
The suggestion that the stroma could limit drug penetration in PDAC was supported
by work in mouse models targeting the ECM component, hyaluronan, which resulted in
normalization of interstitial fluid pressures and microvasculature, and improved efficacy
of gemcitabine [82]. Attempts to translate these concepts to the clinic, however, were
disappointing [83,84].
Subsequent preclinical studies attempted to understand the reasons for these failures.
Genetic models assessing the effects of pancreatic epithelial Shh deletion, chronic pathway
inhibition or depletion of αSMA fibroblasts resulted in more aggressive, poorly differ-
entiated tumours and reduced survival in KPC mice [68,85,86]. Interestingly ‘basal-like’
tumours, which are more undifferentiated, have been shown to have a worse prognosis but
the presence of stromal signatures has been shown to improve their survival [53]. Work by
Steele et al., showed that SHH signalling was enriched in a subset of myCAFs [60], suggest-
ing that pathway inhibition is predominantly affecting this population, and demonstrated
a shift in proportions of CAF subtypes to favour iCAFs upon SHH pathway inhibition [60].
The iCAFs have been shown to release cytokines such as IL-6 [33], which is linked to
cachexia and generally a worse prognosis in PDAC [87], and this may explain the failure of
SHH targeting in the clinic. Insight on this could be gained from Huang et al., who showed
that inhibiting stromal TGFβ-R2, in PDAC in mice lacking TGFβ-R2 in the epithelial cells,
resulted in reduced levels of IL-6 and therapeutic benefit. They found that IL-6 high fi-
broblasts had the highest expression of Tgfbr2, and although canonical TGFβ signalling is
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thought to antagonize iCAFs, TGFβ stimulation of CAFs led to upregulation of IL-6 and
LIF via non-canonical signalling through JunD [88].
Recent studies have sought to target CAF function, rather than ablating whole pop-
ulations. For example, perlecan deletion from KPC tumour-educated CAFs promoted
sensitivity to gemcitabine–abraxane combination therapy in a co-transplant orthotopic
model [71]. In contrast, deletion of collagen I specifically from αSMA+ fibroblasts, acceler-
ated pancreatic tumourigenesis in a dual recombinase mouse model of PDAC. Interestingly
the lack of collagen I in this situation did not affect the proportions of fibroblast subpopula-
tions, as determined by single cell RNA sequencing, but did result in poorly differentiated,
immunosuppressed tumours. Although αSMA is expressed across most CAF subtypes, the
myCAFs exhibit the highest expression and are also the major producers of ECM. Interest-
ingly, collagen I deletion from fibroblast specific protein 1 positive fibroblasts had no effect
on survival [89]. This study does, therefore, suggest that at least a subset of myCAFs may
be tumour suppressive. However, in contrast to these findings, Losartan, an angiotensin
inhibitor with anti-fibrotic effects, previously shown to inhibit collagen I production by
CAFs and reduce stromal collagen in a pancreatic cancer mouse model [90] was able to
reduce both stromal collagen and hyaluronan, potentially via inhibition of TGFβ1, and
allow enhanced drug delivery [91]. Indeed, a phase II trial of Losartan in combination
with FOLFIRINOX showed promise in the locally advanced PDAC setting [92]. Therefore,
further, clarity is required on the role of collagen production by different CAF populations,
and gene deletion in the iCAF subpopulation specifically may enhance this understanding.
Enhanced drug efficacy in tumour cells has been a goal of many studies investigating
stromal manipulation in PDAC. However, conversely, tumour cell-targeted therapies may
also have consequences in the TME and on the CAFs. In general, CAFs appear to be resistant
to gemcitabine in terms of survival, indeed, they have been reported to sequester active
gemcitabine metabolites, thus protecting tumour cells [93]. Their response to treatment can,
however, significantly influence the surrounding cancer cells. For example, gemcitabine
has been shown to promote the release of extracellular vesicles from CAFs, which led to
increased proliferation and drug resistance in the pancreatic tumour cells via increased
snail expression [94]. CAF-derived IGF-1 and IGF-2, as well as SDF1, have also been
implicated in resistance to standard of care chemotherapies in pancreatic cancer [95]. Thus,
it is worth noting that increasing drug penetration alone is unlikely to lead to significant
advances in terms of efficacy. The availability of active drug metabolites and the inhibition
of stromal signals able to confer chemo-resistance are likely to be more important than
drug delivery.
Chemotherapy can also indirectly affect the output of CAFs as a consequence of dereg-
ulated stromal-tumour crosstalk. For example, Abraxane treatment can drive CXCL10
expression by PDAC cells, resulting in diminished CAF secretion of IL-6 and reduced can-
cer cell migration and invasion [96]. Long-term therapy with gemcitabine in PDAC mouse
models was shown to drive increased antigen presentation and immune checkpoint ex-
pression as well as elevated TGFβ signalling and cytokine and chemokine secretion. These
factors resulted in profound changes in the composition of the tumour stroma, rendered
the CAFs resistant to gemcitabine and drove further TGFβ1 release [97]. Treatment with a
combination of gemcitabine, the TGFβ-R1 inhibitor, galunisertib, and immune checkpoint
blockade resulted in restoration of anti-tumour immunity and extended survival in KPC
mice [97]. Of note, an interesting observation of increased CD105 expression was seen
in long-term KPC treated mice tumours, but not in cancer cell lines, which could be of
particular interest with Hutton et al., showing a divergent function of CD105+ CAFs vs.
CD105- CAFs [66].
Of course, care needs to be taken when employing TGFβ-targeting strategies. In the
tumour cells, TGFβ signalling has clear tumour-suppressive effects, and TGFβ inhibition
alone had been shown to exacerbate disease in mice in both early and late intervention
studies [98]. Nevertheless, the TGFβ receptor inhibitor, galunisertib, combined with
gemcitabine, improved overall survival in unresectable patients compared with gemc-
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itabine [99], although this agent has since been discontinued. Inhibition of TGFβ-R2 has
also been shown to reduce collagen deposition and immune suppression in orthotopic
and autochthonous models of PDAC [31]. Further, models with cancer cells bearing
Tgfbr2 mutations showed an increased immune infiltration when treated with a TGFβ-
R2 inhibitor, thereby depleting TGFβ signalling in stromal cells only [88]. In contrast,
Zhang and colleagues found that Tregs represent a significant source of TGFβ ligands in
PDAC and observed that Treg depletion resulted in fibroblast reprogramming towards
an inflammatory phenotype, with myeloid cell recruitment, immune suppression and
accelerated tumourigenesis [100].
Cytokine education of CAFs has also been shown to impact on their function and may
yet provide a therapeutic opportunity. For instance, IL-17 deletion in the KPC mouse altered
the TME compared to controls, with increased IL-17F in the serum and higher expression
of its receptor specifically in the CAFs in IL-17 deficient tumours. The CAFs from IL-17
deficient tumours exhibited significant gene expression changes including elevated TGFβ
signalling components. Fibrosis was enhanced but crucially, the stroma was of a less
compact and more immune-permissive nature resulting in increased T cell infiltration and
suggesting the use of IL-17 inhibitors as part of combinatorial strategies [101].
These studies all point to an important role for TGFβ signalling in the wider PDAC
TME, but further work is needed to understand how this can be translated safely for
therapeutic benefit. The pancreatic cancer stroma is generally believed to be an immuno-
suppressive environment, and this is likely mediated in part by the secretion of immuno-
suppressive factors such as TGFβ since TGFβ can regulate the function of many different
immune cell types [102]. TGFβ signalling in the tumour stroma has been implicated in
resistance to immunotherapy and studies in mouse models of other tumour types have
shown that immunotherapy can synergise with TGFβ blockade [103,104]. In pancreatic
cancer, predominance of the TGFβ-driven, LRRC15+ CAF population correlated with poor
outcome in response to immune checkpoint blockade [61], whilst a phase I trial of M7824, a
bifunctional fusion protein designed to simultaneously target TGFβ signalling and PD-L1,
showed promise in a small number of pancreatic cancer patients [105]. A role for TGFβ in
suppressing cytotoxic T cell function in PDAC has been described, with TGFβ inhibition
leading to increased PD-L1 expression and abrogation of anti-tumour immunity [30,106].
Thus, the combination of TGFβ inhibition with immune checkpoint blockade has been
investigated by several groups. Studies in mice have shown that inhibition of TGFβ with
checkpoint inhibition can improve survival, with reduced fibrosis leading to increased
infiltration of T cells and immune checkpoint blockade enhancing cytotoxicity [106,107].
These findings also have a bearing on the potential of radiotherapy to treat PDAC. Targeted
radiotherapy can drive an adaptive immune response due to the release of tumour cell
antigens, however, this can be mitigated by inflammation driving stromal remodelling and
a more fibrotic, immune suppressed TME. In fact, Lan and colleagues found that simulta-
neous targeting of TGFβ and PD-L1, in combination with radiotherapy, prolonged survival
in mouse models of several cancers, including pancreatic cancer [108]. Together, these data
highlight potential therapeutic avenues that could be explored to bolster TGFβ therapy.
TGFβ targeting may also have consequences in other immune cells that could be
harnessed as part of combinatorial approaches. For example, TGFβ can negatively influ-
ence the tumour immune response via its capacity to inhibit the maturation and antigen-
presenting ability of dendritic cells, as well as to dampen the activity of effector T cells and
promote Tregs [102]. Adoptive transfer of chimeric antigen receptor (CAR)-engineered T
cells is a promising novel therapeutic strategy for cancer, due to the ability to target virtually
any tumour associated antigen. In PDAC, target antigens currently under investigation
include integrin αvβ6, CD276, CD24, prostate stem cell antigen (PSCA), carcinoembryonic
antigen-related adhesion molecule 7 (CEACAM7), MUC1, mesothelin, FAP and Her-2 [109].
However, the immune-suppressed TME has limited the efficacy of this approach in solid
tumours, at least in part due to the effects of TGFβ signalling [110]. Thus, inhibiting TGFβ
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signalling, or even engineering TGFβ-resistant CAR T cells, could offer hope for the future
of CAR T cell therapy in PDAC.
In conducting pre-clinical and clinical trials there is now a clear need to measure
the impact treatment has upon the wider TME, especially the CAFs, not only to better
understand the biology, but also to reveal vulnerabilities that may suggest combinatorial
or second-line strategies. For instance, the TGFβ inhibitor combinatorial trials described
above have demonstrated moderate efficacy in patients, but it would of course be useful
to know how therapy affected CAF subpopulations. Further study should dissect where
inhibition of TGFβ signalling is having the biggest effect in these tumours, whether through
disrupting CAF pro-tumorigenic function or via relieving immune suppression, or more
likely, both (as illustrated in Figure 3). Further, with reciprocal signalling shown between
CAFs and cancer cells [47], understanding how treatment affects this communication is
key. For instance, short term SHH inhibition was shown to cause an increase in cancer
cell specific pERK signalling [66], while long term gemcitabine treatment increased TGFβ
signalling [97]. Understanding CAFs in the developing PDAC is essential, but so too is
identifying the changes in patients who have undergone therapy, as this may expose key
targets or highlight resistance mechanisms.
Figure 3. TGFβ secretion by CAFs impacts multiple cell types in pancreatic cancer.
7. Concluding Remarks
Over the past few years, advances in our understanding of the heterogeneity of
CAFs in the pancreatic cancer microenvironment have offered renewed hope that stromal-
targeted therapies could still hold promise in this disease. It is clear from functional studies,
however, that CAF heterogeneity is not restricted simply to expression of specific markers,
and that populations exist that exhibit both tumour-promoting and tumour-restrictive
behaviours. Therefore, rational approaches to target tumour-promoting CAF behaviour,
rather than targeting all CAFs, will be required. This could be achieved by converting
tumour-promoting CAFs into a more tumour-suppressive phenotype, ablation of a tumour-
promoting population, targeting of specific tumour-promoting secreted chemokines or
cytokines, such as TGFβ, or by a combination of these approaches. It is likely that any
effective regimen will also include chemotherapy and potentially immune-targeting ther-
apy, and that patient stratification will be important. It is clear, however, that in order to
elucidate how different populations can be targeted but also to understand the effects of
subtype targeting in complex systems, a great deal more work is required.
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